EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Alpha-synuclein and microglia in Parkinson’s disease and multiple system atrophy: A comprehensive review

Jamir Pitton Rissardo, Ana Letícia Fornari Caprara

Brain Circulation · 2026-10 · 12 (4) · 351-361

DOI: 10.4103/bc.bc_75_25 ↗
AbstractBibliografische Angaben

Abstract

Abstract: Beyond its direct neuronal effects, alpha-synuclein (α-synuclein) interacts with microglia, influencing disease progression through mechanisms that are not fully understood. Microglia may contribute to the propagation of α-synuclein pathology through pathophysiological pathways such as incomplete degradation and intercellular transfer of aggregates. Research into α-synuclein-microglia interactions has revealed their dual role in aggregate clearance and inflammation, highlighting microglia as both protective and deleterious agents in synucleinopathies. Human genetics suggest that neuronal-glial crosstalk plays a causal role in α-synucleinopathies. Leucine-rich repeat kinase 2 (LRRK2) may originate in the microglia based on studies with induced pluripotent stem cells (iPSCs). Other IPSC-derived microglia were glycoprotein nonmetastatic melanoma protein B and lysolipid transporter 1 (SPNS1) in Parkinson’s disease (PD). Another source of α-synuclein could be neuronal, and the discovery of cyclic guanosine monophosphate–adenosine monophosphate (AMP) synthase/stimulator of interferon genes leading to stimulation of interferons and LRRK2, especially in dopamine neurons, is a supporting finding. Multiple system atrophy (MSA) is an oligodendroglial disease, and some of the targets for management may involve mitochondrial dysfunction, iron deposition, lipid droplets, cytoskeleton disruption, proteasome dysfunction, and tubulin polymerization, promoting protein-like proteins containing p25α. The aim of this review is to provide a comprehensive overview of the molecular and cellular mechanisms linking α-synuclein and microglial activation in PD and MSA, with a focus on genetic insights, autophagy-related pathways, and emerging therapeutic targets.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →